Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — FY2016 Q2 Earnings Presentation
68 slides from Daiichi Sankyo's earnings presentation, Nov 1, 2016
Slide 1: Top Management Presentation: Financial Results for FY2016 Q2
Top Management Presentation Financial Results for FY2016 Q2 (April 1 – September 30, 2016) DAIICHI SANKYO CO., LTD Joji Nakayama President and CEO November 1, 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi
Slide 3: Agenda
Agenda FY2016 Q2 Financial Results FY2016 Revised Consolidated Forecast Progress of 5-Year Business Plan R&D Update 2
Slide 4: FY2016 Q2 Financial Results
FY2016 Q2 Financial Results 3
Slide 5: Overview of FY2016 Q2 Results
Overview of FY2016 Q2 Results (JPY Bn) FY2015 Q2 YTD FY2016 Q2 YTD YoY Results Results -4.3% Revenue 478.8 458.0 -20.8 Cost of Sales 148.9 147.3 -1.7 SG&A Expenses 144.5 141.7 -2.8 R&D Expenses 88.4 95.8 +7.4 -24.5% Operating Profit 97.0 73.3 -23.7 Profit before Tax 90.8 71.9 -18.9 -30.7% Profit att
Slide 6: Revenue
Revenue Decreased by 20.8 Bn JPY • Increase in Japan, Luitpold and Europe • Decrease in DSI and ASCA • Negative forex impact by yen appreciation (JPY Bn) FY2015 Results 478.8 Japan Positive : Tenelia +6.4 Lixiana +6.1 Japan Nexium +3.4 Efient +3.1 18.3 Memary +2.9 Pralia +2.9 (incl. Vaccines, OTC) R
Slide 7: Operating Profit
Operating Profit Decreased by 23.7 Bn JPY • Decrease in revenue • Increase in R&D expenses by progress of projects, and special items included in FY2015 • SG&A cost reduction and positive forex impact on expenses (JPY Bn) Revenue -20.8 FY2015 Results 97.0 incl. forex impact -28.7 Revenue 76.2 20.8 S
Slide 8: Special Items
Special Items (JPY Bn) FY2015 Q2 YTD Results FY2016 Q2 YTD Results YoY Gain on sales of subsidiary -2.4 Cost of Sales ‐ +3.5 Gain on sales of fixed assets -1.1 SG&A Expenses Gain on sales of fixed assets -8.2 Restructuring costs 6.0 +14.2 R&D Expenses ‐ - - Total -11.7 6.0 +17.7 - : Cost decrease it
Slide 9: Profit Attributable to Owners of the Company
Profit Attributable to Owners of the Company Decreased by 21.7 Bn JPY • Decrease in operating profit • Increase of income taxes caused by decrease in R&D tax credit (JPY Bn) FY2015 Results 70.7 Operating Profit 23.7 Financial Income / Expenses -4.7 FY2015: Expenses relating to the sales of Sun Pharm
Slide 10: Major Business Units
Major Business Units (JPY Bn) FY2015 FY2016 vs. Forecast* Q2 YTD Q2 YTD YoY (%) Results Results Japan 227.8 239.0 +11.2 47.8% Daiichi Sankyo Healthcare 24.6 32.2 +7.6 49.5% Daiichi Sankyo Inc. 93.4 70.3 -23.1 53.2% Olmesartan 57.1 36.7 -20.5 53.9% Welchol 24.2 19.5 -4.7 54.1% Effient 10.6 10.8 +0.2
Slide 11: Major Products in Japan
Major Products in Japan (JPY Bn) FY2015 FY2016 vs. Forecast* Q2 YTD Q2 YTD YoY (%) Results Results Nexium ulcer treatment 38.7 42.0 +3.4 50.7% Olmetec antihypertensive agent 36.2 34.9 -1.3 51.3% Alzheimer’s disease Memary treatment 20.5 23.4 +2.9 45.9% Loxonin anti-inflammatory analgesic 24.4 18.8 -
Slide 12: FY2016 Revised Consolidated Forecast
FY2016 Revised Consolidated Forecast 11
Slide 13: FY2016 Revised Consolidated Forecast
FY2016 Revised Consolidated Forecast (JPY Bn) FY2016 FY2016 Major factors vs. Forecast Forecast Forecast -Forex impact -25.0 (as of May.) (as of May.) (as of Oct.) -Japan +9.0 -Overseas +16.0 Revenue 920.0 920.0 0.0 Major factors Cost of Sales 320.0 307.0 -13.0 -Forex impact -9.0 -Cost reduction -6.
Slide 14: Progress of 5-Year Business Plan
Progress of 5-Year Business Plan 13
Slide 15: Business Strategy
Business Strategy Strategic Target 1:Grow Edoxaban Strategic Target 2:Establish Oncology Business Strategic Target 3:Grow as No.1 company in Japan Strategic Target 4:Expand US Businesses Strategic Target 5:Continuously Generate Innovative Medicine Changing Standard of Care (SOC) Strategi
Slide 16: Strategic Target 1: Grow Edoxaban
Strategic Target 1:Grow Edoxaban 15
Slide 17: Growth of Edoxaban
Growth of Edoxaban Grow sales with the expanding DOAC market Sustainable Growth (2021-) New Evidence ( -2020) Maximize brand value Launch (2015-2017) Launch in major countries FY2015 FY2016 FY2017 FY2018 FY2019 FY2020 FY2021- DOAC market Edoxaban 16
Slide 18: Edoxaban: Launch & Alliance
Edoxaban: Launch & Alliance Expand launched countries Expand alliance Italy, Spain, Taiwan (Sep. 2016) Partner with Servier Canada inc.** in Canada Belgium, Hong Kong (Oct. 2016) (Jun. 2016) Growing market share in Germany and South Korea* Germany: 3.2% (Apr.)→4.3% (Jul.) South Korea: 3.4% (Ap
Slide 19: Edoxaban: Growth in Japan
Edoxaban: Growth in Japan Latest market share reached: 16.0% (Jul. 2016 - Sep. 2016) (%) 50 40 30 Lixiana Product A Product B 20 Product C Market Share: 16.0% 10 0 FY2014Q2 FY2014Q3 FY2014Q4 FY2015Q1 FY2015Q2 FY2015Q3 FY2015Q4 FY2016Q1 FY2016Q2 Copyright © 2016 QuintilesIMS Calculated based on JPM 2
Slide 20: Edoxaban Clinical Research Program (1)
Edoxaban Clinical Research Program (1) Ongoing randomized controlled trials in various clinical settings Clinical Setting Primary Primary (Comparator) Outcome Completion Cardioversion • Stroke, SEE, MI, CV mortality Presented at (enoxaparin/warfarin) • Major and CRNM bleeding ESC 2016 PCI (VKA) • Ma
Slide 21: Edoxaban Clinical Research Program (2)
Edoxaban Clinical Research Program (2) Ongoing non-interventional studies to generate real-world data with more than 60,000 patients Prolongation PREFER in AF Edoxaban Treatment in routiNe PREvention oF thromboembolic clinical prActice in Patients with events-European Registry in non valvular Atrial
Slide 22: Strategic Target 2: Establish Oncology Business
Strategic Target 2:Establish Oncology Business 21
Slide 23: Progress in Late Stage Pipeline
Progress in Late Stage Pipeline Summary of update since 5YBP publication written in red TLR:anticipated Top Line Result Acute myeloid • Orphan Drug Designation by the FDA and EMA leukemia (AML) • Fast Track Status by the FDA 2nd line (P3) • Targeting patients with FLT3-ITD mutation Quizartinib DMC I
Slide 24: Progress in Early Stage Pipeline
Progress in Early Stage Pipeline Summary of update since 5YBP publication written in red • Demonstrated activity in patients resistant to Herceptin or Kadcyla DS-8201 Solid tumor • Validates DS proprietary ADC* technology • Early phase 1 data reported at ESMO Congress (Oct 2016) (HER2-ADC) (P1) * An
Slide 25: Strategic Target 3: Grow as No.1 company in Japan
Strategic Target 3:Grow as No.1 company in Japan 24
Slide 26: Grow as No.1 company in Japan
Grow as No.1 company in Japan Many of innovative major products reached No. 1 share and continue to expand market share 97.2 Bn Nexium (ulcer treatment) 100 +19.6 Bn Reached No. 1 share in Jan. 2014 with rapid expansion and continue to expand market share 77.6 Bn 80 Memary (Alzheimer’s disease t
Slide 27: Other Updates
Other Updates Launched anti epilepsy VIMPAT and filed an new indication Launched in Aug. 2016 as an adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy and filed in Aug. 2016 for partial amendment of approval to add a new indication in mono therapy for partial-o
Slide 28: Strategic Target 4: Expand US Businesses
Strategic Target 4:Expand US Businesses 27
Slide 29: DSI: Licensed abuse-deterrent opioids
DSI: Licensed abuse-deterrent opioids Licensed two abuse-deterrent formulations including MorphaBond™ MorphaBond™ The agreement also provides Compound Morphine ER Daiichi Sankyo, Inc. with the (ADF*) rights to commercialize a separate investigational Development Approved in US Stage (Oct 5, 2015) In
Slide 30: The Epidemic of Opioid Prescription Abuse is Real in US
The Epidemic of Opioid Prescription Abuse is Real in US 12,000,000 425,000 16,650 non-medical Rx opioid ER visits from accidental fatal overdoses involving Rx users*in 2010 opioid overdoses* in 2010 opioids* in 2010 How Does Abuse Occur? • The intent of abusers is to extract the opioid as fast as po
Slide 31: Growing number of federal and state initiatives
Growing number of federal and state initiatives to address the epidemic of abuse Abuse Deterrent Formulations (ADF) are one part of the multifaceted solution to the opioid epidemic FDA has created a multi-faceted Action Plan. They are on record stating it has the authority to remove non-ADF opioid
Slide 32: DSI: Expand Pain Franchise
DSI: Expand Pain Franchise Two ADF products are complementary and requires no additional headcount Morphine ER (ADF*) FDA Approved 2015.10.5 Management of severe pain** MorphaBond Mirogabalin MOVANTIK Fibromyalgia Opioid-Induced Constipation Phase 3 CY2015 CY2016 CY2017 CY2018 CY2019 CL-108 Second I
Slide 33: DSI Pain Franchise: Target Segment
DSI Pain Franchise: Target Segment Large Market with Diverse Segments 330~ Million TRx Market size $28 billion Mirogabalin SNRIs† TCAs† 1% Anesthetics 1% CL-108 Anti-migraine Pregabalin Acute Anti-epileptics † IRO* (<15 days) TRx by Segment Non-narcotic analgesics Other Non-Acute IRO* IRO* (>15 days
Slide 34: CL-108: Initiate OINV education
CL-108: Initiate OINV education Expand DSI presence in Pain management community Opioid-Induced Constipation MOVANTIK Start DTC to educate OIC May 2015 Start co-promotion CY2015 CY2016 CY2017 CY2018 CY2019 Start OINV education activity Starting promotion(Planned) CL-108 Pain & Opioid-Induced Nausea
Slide 35: OINV education
OINV education August 2016 started multi-channel campaign to educate about OINV for 70,000 HCP Started as of August 15, 2016 www.knowOINV.com 34
Slide 36: OINV education
OINV education Various conventions across the country 35
Slide 37: DSI Commitments in Pain Care
DSI Commitments in Pain Care Inappropriate usage of opioids (i.e. diversion, misuse, abuse, addiction, or overdose) has become an epidemic in the US. DSI launched www.CommitmentsinPainCare.com, which hosts an overview of our company’s approach to responsible pain management and our dedication to bei
Slide 38: LPI: Growth of Injectafer
LPI : Growth of Injectafer Injectafer* drivesthe Injectfer drives thegrowth growthofofUS USIVIVIron IronMarket Market Market Now share has its market reached share reach27% 27%in interms termsof ofMAT MAT IV Iron $ sales As of Mid-term plan (includes dialysis) Latest announcement + 15.1% + 13.6% 800
Slide 39: Collaboration between DSI and LPI
Collaboration between DSI and LPI To maximize sales potential of Injectafer, LPI / DSI collaboration starts from January 2017 Women’s Etiologies of IDA Health Chronic IBD/ Heart ND-CKD Rheum Oncology (post-partum, Celiac/ pregnancy, Other Failure GI HUB) IDAs Patients’ Visit to Hospitals / Clinics /
Slide 40: Strategic Target 5: Continuously Generate Innovative Medicine Changing SOC
Strategic Target 5:Continuously Generate Innovative Medicine Changing SOC 39
Slide 41: Partnership with Academia and Biotech
Partnership with Academia and Biotech Collaboration with Dana-Farber Create new drugs Lung cancer Cancer Institute to evaluate DS therapeutics in Oncology/New compounds including HER3-ADC Horizon area Immune-Oncology Collaboration with AgonOx Collaboration with Professor Todo, Realize clinical Oncol
Slide 42: Progress towards Clinical Application of Innovative Technology
Progress towards realization for Clinical Application of Innovative Technology Red: update since 5YBP publication Presented Part 1 data at the ESMO 2016 3 rd wave phase 1 Business value opportunities DS-8201(HER2-ADC) DS-5141 Peptide DS-8895 Nucleic acid DS-5573 U3-1402 (HER3-ADC) 2nd wave Cel
Slide 43: Shareholder Returns
Daiichi-Sankyo Shareholder Returns 42
Slide 44: Shareholder Returns
Shareholder Returns Shareholder Returns Policy during 5YBP* Total return ratio: 100% or more Annual ordinary dividend: more than 70 JPY Flexible acquisition of own shares * 5YBP: 5-year Business Plan (FY2016 - FY2020) Acquired our own shares based on the policy Acquisition period: From June
Slide 45: R&D Update
R&D Update Glenn Gormley MD PhD Senior Executive Officer Global Head of R&D Daiichi Sankyo Co., Ltd 44
Slide 46: Major Update in R&D Pipeline in Q2 FY2016
Major Update in R&D Pipeline in Q2 FY2016 Pre- Regulatory Discovery Phase 1 Phase 2 Phase 3 Review clinical Lung Cancer Denosumab Esaxerenone Started (CS-3150) Submitted NDA Immune collaboration in Japan for Oncology with Dana- Started phase Rheumatoid Farber Cancer 3 study for Arthritis Started Ins
Slide 47: DS-8201: Structure
DS-8201: Structure O Drug: Anti-HER2 mAb Protease cleavable Linker O Topoisomerase I inhibitor OH (DXd) O O N O Protease H O N H O H O H O H N digestion S N N N N N N N O O H H H N O O O O F F N O O H O DS-8201a Kadcyla (T-DM1) Antibody Anti-HER2 mAb Trastuzumab (Tmab) Payload Topoisomerase* DAR: I
Slide 48: Breast cancer patient journey: No good treatment options
Breast cancer patient journey: No good treatment options for patients who fail Kadcyla or with low HER2 expression Treatment Line Surgery / HER2 positive Radiation (w/ Local treatment Local Adjuvant) High Herceptin + Metastatic 1st line systemic Perjeta + Taxane Low Kadcyla / Tykerb 2nd line systemi
Slide 49: DS-8201 Phase 1 Study: Study Design
DS-8201 Phase 1 Study: Study Design Open Label, Multiple Dose, First-in-Human Study Part 1: Dose Escalation in Japan • Advanced/Unresectable or metastatic Breast Cancer or Gastric Cancer or GEJ* adenocarcinoma • Refractory to or intolerable with standard treatment, or for which no standard treatme
Slide 50: DS-8201 Phase 1 Study: Patient Demographics
DS-8201 Phase 1 Study: Patient Demographics Patient characteristics HER2 Status Number of patients IHC treated 22 0 1 Age median (range) 66 (38-79) 1+ 3 2+ 3 Number of Prior Chemotherapy 3+ 15 Regimens 5 (1-11) (range) Prior therapy Anti-HER2 Therapy 18 Tumor type Trastuzumab 18 Breast 16 Pertuzumab
Slide 51: DS-8201 Phase 1 Study: Efficacy (% change)
DS-8201 Phase 1 Study: Efficacy (% change) Best percent change of tumor volume from baseline ORR* was 35% (7 PRs) *ORR (Objective Response Rate) : CR + PR **DCR (Disease Control Rate): CR + PR + SD DCR** was 90% CR: Complete Response Disappearance of all target lesions PR: Partial Response At leas
Slide 52: DS-8201 Phase 1 Study: Efficacy in Kadcyla pre-treated patients
DS-8201 Phase 1 Study: Efficacy in Kadcycla pre-treated patients Subgroup Results in Kadcyla (T-DM1) pre-treated patients with HER2-positive Breast Cancer Kadcyla pre-treated N= 12 (1 patient without result) Ineffective CR, PR or SD Discontinued due to refractory or AE DS-8201 12 patients ORR (Objec
Slide 53: Summary of Safety and Tolerability
Summary of Safety and Tolerability MTD* was not reached in 0.8~8.0 mg/kg tri-weekly cohorts No DLT**, or cardio toxicities at any dose level so far Most common adverse events (AEs) were mild or moderate gastrointestinal and hematological events *MTD: Maximum Tolerated Dose **DLT: Dose Limiting
Slide 54: Highlights of ESMO 2016 session
“Highlights of ESMO 2016” session
Slide 55: CS-3150 (esaxerenone)
CS-3150 (esaxerenone) CS-3150 is a Non-steroidal Mineralocorticoid Receptor (MR) antagonist licensed from Exelixis with : High MR selectivity Superior preclinical MR antagonistic effects vs eplerenone Long half-life (20hrs) Target indication and development status in Japan Hypertension :
Slide 56: Esaxerenone: MOA
Esaxerenone: MOA Aldosoterone MR esaxerenone Tubular epithelia Non-epithelial tissue ・ Na+ reabsorption / K+ excretion ・ Inflammation, ROS production ・ Fibrosis ・ Body fluid retention ・ Activation of sympathetic nerve • Hypertension • Hypertension • Serum electrolyte homeostasis • Heart failure • CK
Slide 57: Unmet Medical Need in Diabetic Nephropathy (DN)
Unmet Medical Need in Diabetic Nephropathy (DN) There is an Increased incidence in patients diagnoss with diabetes and one third develop DN1) Without appropriate treatment at an early stage, patients often progress to renal failure which can require hemodialysis2) Medical cost of hemodialysis
Slide 58: Esaxerenone: Hypertension
Esaxerenone: Hypertension Phase 2b Study Results change from baseline in sitting blood pressure at the end of treatment CS-3150 CS-3150 CS-3150 Eplerenone Placebo 1.25mg 2.5mg 5mg 100mg 0 0 Least Squares Mean Change -5 -5 -3.8 -5.0 (mmHg) ** -10 -7.0 -7.6 -10 -8.5 ** * -10.4 -10.7 -15 -15 ** -14.3
Slide 59: Esaxerenone: Hypertension
Esaxerenone: Hypertension Japan phase 3 study design CS-3150 5 mg CS-3150 2.5 mg follow-up Washout period (4 wks) Eplerenone 50mg (1 wk) 12 weeks Objectives Primary objective: non-inferior antihypertensive effect to EPLERENONE Duration Washout: 4 weeks, Treatment: 12 weeks Sample size 930 pts. ( 3
Slide 60: Esaxerenone: Diabetic Nephropathy (DN)
Esaxerenone: Diabetic Nephropathy (DN) Japan phase 2b study CS-3150 0.625 mg/day (n=73) CS-3150 1.25 mg/day (n=73) Include ARB or ACEi CS-3150 2.5 mg/day (n=72) follow-up therapy period CS-3150 5 mg/day (n=74) (6 wks) (4-12 wks) Placebo (n=73) 12 weeks ARB or ACEi dose-dependent efficacy and safet
Slide 61: Primary Endpoint: UACR change from baseline
Primary Endpoint: UACR*change from baseline at end of treatment *UACR: Urine Albumin-to-Creatinine Ratio Placebo 0.625mg 1.25mg 2.5mg 5mg 20.0 Geometric mean percent change (%) 10.0 0.0 -10.0 -20.0 -30.0 -7 -40.0 -21 -50.0 -38 -60.0 -50 -70.0 -56 *** *** *** p<0.0001 *** Significant UACR reduction v
Slide 62: Safety data for DN study
Safety data for DN study Incidence of Hyperkalemia Placebo 0.625 mg 1.25mg 2.5 mg 5.0mg N=72 N=71 N=72 N=70 N=73 n n n n n Confirmed Hyperkalemia Serum K ≥ 6.0 mEq/L or two Successive Measurements of 1 2 2 2 7 Serum K ≥ 5.5 mEq/L Confirmed hyperkalemia was comparable to placebo at 0.625-2.5mg but nu
Slide 63: Major Update in R&D Pipeline in Q2 FY2016
Major Update in R&D Pipeline in Q2 FY2016 Pre- Regulatory Discovery Phase 1 Phase 2 Phase 3 Review clinical Lung Cancer Denosumab Esaxerenone Started (CS-3150) Submitted NDA Immune collaboration in Japan for Oncology with Dana- Started phase Rheumatoid Farber Cancer 3 study for Arthritis Started Ins
Slide 64: Reference
Dalichi-Sankyo 63
Slide 65: Major R&D milestone events
Major R&D milestone events Project Indication/Study Event Target Pain/Opioid-induced nausea and vomiting PDUFA date CL-108 (US) Approval Jan. 31, 2017 Denosumab Rheumatoid arthritis (JP) Approval FY2017 CHS-0214 Rheumatoid arthritis (JP) NDA FY2016 (etanercept BS) METIV・HCC Hepatocellular carcinoma
Slide 66: Major R&D Pipeline
Major R&D Pipeline As of October 2016 Therapeutic area Phase 1 Phase 2 Phase 3 Application DS-3032 (US/JP) DS-8895 (JP) Patritumab (EU) Tivantinib (US/EU) (MDM2 inhibitor) (Anti-EPHA2 antibody) (U3-1287 / Anti-HER3 antibody) (ARQ 197 / HCC / MET inhibitor) PLX7486 (US) DS-8273 (US) Deno
Slide 67: DS R&D Day 2016
DS R&D Day 2016 Date: December 13, 2016 (15:30 – 17:00) Location: Daiichi Sankyo Co. Ltd Nihonbashi HQ Speakers: Dr. Glenn Gormley (Sr. Executive Officer, Global R&D head) Dr. Antoine Yver (Global head of Oncology R&D, Head of Daiichi Sankyo Cancer Enterprise) and Others 66
Slide 68: Corporate Communications Department
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126
Daiichi Sankyo Company — FY2016 Q2 Earnings Presentation on 6ix